Distribution and drug resistance of Escherichia coli producing extended-spectrumβlactamases in cancer patient
10.3969/j.issn.1673-4130.2016.08.015
- VernacularTitle:肿瘤患者产超广谱β-内酰胺酶大肠埃希菌的临床分布及耐药性分析
- Author:
Li ZHAI
;
Wencong LI
;
Fengli GUO
;
Li YANG
- Publication Type:Journal Article
- Keywords:
Escherichia coli;
extended-spectrum βlactamases;
clinical distribution;
drug resistance
- From:
International Journal of Laboratory Medicine
2016;37(8):1052-1054
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the distribution ,specimen types and characteristics of antibiotic resistance of Escherichia coli producing extended‐spectrum βlactamases(ESBLs) of the hospital in 2013 and to guide clinical drug use .Methods Analyzed the distribution and antibiotic resistance for the 375 strains of ESBLs‐producing E .coli ,and ESBLs was detected by disk diffusion phe‐notypic confirmatory test .Results The major distribution department was gynecology department which accounted for 42 .67% , followed by uropoiesis surgical department which accounted for 14 .67% ;the major specimen type was urine(55 .2% ) ,followed by puncture fluid(15 .47% )and excretion(14 .67% ) .For the 375 isolates of ESBLs‐producing E .coli ,the resistance rates to cefazolin , cefuroxime ,cefoperazone and cefotaxime were 100 .00% ,to SMZco was 78 .10% ,while the resistance rate to imipenem was 0 .00% , and to amikacin and fosfomycin were 4 .30% and 10 .10% respectvely ,the resistance rates to piperacillin/tazobactam and aztreonam were 17 .10% and 66 .70% respectvely .Conclusion ESBLs producing Escherichia coli have severe multidrug resistance .Antibiotics should be chosen and used rationally in accordance with results of drug susceptibility testing ,meanwhile the monitoring of ESBLs′infection rate and drug resistance should be strengthened .
